secwatch.observer — SEC 8-K summary
======================================

Issuer:     TELA Bio, Inc. (TELA)
CIK:        0001561921
Form:       8-K
Filed at:   2024-06-06T23:59:59+00:00
Accession:  0001104659-24-069099
Event type: leadership
Sentiment:  neutral
Materiality: 0.45
Item codes: 5.02, 5.07, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TELA Bio appoints Jeffrey Blizard to Board; stockholders re-elect directors
---------------------------------------------------------------------------

- Jeffrey Blizard, Global Head of Surgical Sales at Abiomed (J&J MedTech), appointed to Board as Class III director, term to 2025 annual meeting.
- Initial equity grant: option for 9,300 shares vesting monthly over 36 months and RSU for 6,375 shares vesting in three annual installments.
- Annual retainer: $45,000 for Board service plus $5,000 for Nominating Committee.
- Stockholders elected Kurt Azarbarzin (17,037,112 for) and Antony Koblish (18,742,180 for) as Class II directors; KPMG ratified as auditor for FY2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1561921/000110465924069099/0001104659-24-069099-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1561921/000110465924069099/tm2416416d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-069099

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer